Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Dimesylate, Lis-dexamfetamine
2. Dimesylate, Lisdexamfetamine
3. Elvanse
4. Lis Dexamfetamine Dimesylate
5. Lis-dexamfetamine Dimesylate
6. Lisdexamfetamine
7. Nrp 104
8. Nrp-104
9. Nrp104
10. Vyvanse
1. Vyvanse
2. 608137-33-3
3. Nrp-104
4. Lisdexamfetamine Mesilate
5. Spd489
6. Tyvense
7. Nrp104
8. Spd-489
9. Lisdexamfetamine Dimesylate [usan]
10. Lisdexamfetamine Dimesilate
11. Sjt761gegs
12. Lisdexamphetamine Dimesilate
13. L-lysine-d-amphetamine Dimesylate
14. Lisdexamfetamine Dimethanesulfonate
15. (2s)-2,6-diamino-n-[(1s)-1-methyl-2-phenylethyl]hexanamide Dimethanesulfonate
16. Lis-dexamfetamine Dimesylate
17. Lisdexamfetamine Mesilate (jan)
18. Lisdexamfetamine Dimesylate (usan)
19. Lisdexamfetamine Mesylate
20. Nrp 104
21. Lisdexamfetamine Mesilate [jan]
22. (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic Acid
23. Unii-sjt761gegs
24. Venvanse
25. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulfonate
26. Lys-amp
27. Spd 489
28. Lys-d-amp
29. Elvanse (tn)
30. Vyvanse (tn)
31. Schembl678421
32. Chembl1201178
33. Dtxsid60209653
34. Lisdexamfetamine Dimesylate Solution
35. Bcp24044
36. Akos030254940
37. Lisdexamfetamine Mesilate [mart.]
38. Ldx
39. Lisdexamfetamine Mesilate [who-dd]
40. Lisdexamfetamine Dimesylate [vandf]
41. D04747
42. Lisdexamfetamine Dimethanesulfonate [mi]
43. Lisdexamfetamine Dimesylate [orange Book]
44. 137l333
45. Q27289243
46. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulphonate
47. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulfonate
48. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulphonate
49. Ldx;lisdexamfetamine Mesilate;lisdexamfetamine Mesylate;nrp 104;nrp-104;spd 489
50. Lisdexamfetamine Dimesylate Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 455.6 g/mol |
|---|---|
| Molecular Formula | C17H33N3O7S2 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Exact Mass | 455.17599275 g/mol |
| Monoisotopic Mass | 455.17599275 g/mol |
| Topological Polar Surface Area | 207 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 344 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 4 | |
|---|---|
| Drug Name | Lisdexamfetamine dimesylate |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 70mg; 20mg |
| Market Status | Tentative Approval |
| Company | Mylan Pharms; Amneal Pharms; Roxane |
| 2 of 4 | |
|---|---|
| Drug Name | Vyvanse |
| PubMed Health | Amphetamine (By mouth) |
| Drug Classes | Amphetamine |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 20mg; 70mg |
| Market Status | Prescription |
| Company | Shire Development |
| 3 of 4 | |
|---|---|
| Drug Name | Lisdexamfetamine dimesylate |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 70mg; 20mg |
| Market Status | Tentative Approval |
| Company | Mylan Pharms; Amneal Pharms; Roxane |
| 4 of 4 | |
|---|---|
| Drug Name | Vyvanse |
| PubMed Health | Amphetamine (By mouth) |
| Drug Classes | Amphetamine |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 20mg; 70mg |
| Market Status | Prescription |
| Company | Shire Development |
Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
Dopamine Uptake Inhibitors
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-01-28
Pay. Date : 2020-01-21
DMF Number : 22442
Submission : 2009-01-27
Status : Active
Type : II
NDC Package Code : 49812-0186
Start Marketing Date : 2012-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-12-30
Pay. Date : 2021-11-18
DMF Number : 35645
Submission : 2021-11-23
Status : Active
Type : II
NDC Package Code : 51634-2058
Start Marketing Date : 2021-12-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
NDC Package Code : 62207-024
Start Marketing Date : 2024-10-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-21
Pay. Date : 2023-10-12
DMF Number : 38874
Submission : 2023-10-20
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-07-02
Pay. Date : 2018-05-22
DMF Number : 32289
Submission : 2018-05-18
Status : Active
Type : II
NDC Package Code : 61960-0300
Start Marketing Date : 2018-03-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2020-07-28
Pay. Date : 2020-06-03
DMF Number : 34823
Submission : 2020-05-29
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32210
Submission : 2017-11-22
Status : Inactive
Type : II
NDC Package Code : 0406-0248
Start Marketing Date : 2020-05-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-21
Pay. Date : 2023-10-12
DMF Number : 38874
Submission : 2023-10-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-01-28
Pay. Date : 2020-01-21
DMF Number : 22442
Submission : 2009-01-27
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2021-12-30
Pay. Date : 2021-11-18
DMF Number : 35645
Submission : 2021-11-23
Status : Active
Type : II
USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2025-04-21
Pay. Date : 2025-04-08
DMF Number : 38667
Submission : 2023-08-03
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36325
Submission : 2021-10-25
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20103
Submission : 2006-12-29
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-07-02
Pay. Date : 2018-05-22
DMF Number : 32289
Submission : 2018-05-18
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32210
Submission : 2017-11-22
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2020-07-28
Pay. Date : 2020-06-03
DMF Number : 34823
Submission : 2020-05-29
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35754
Submission : 2021-05-28
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Veranova is a global leader in developing and manufacturing specialist and complex APIs for pharma and biotech customers, with over 50 years of experience supporting the healthcare...
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
About the Company : Noramco, founded in 1979, specializes in developing and manufacturing APIs for opioid and non-opioid products. It excels in controlled substance development, offering supply-chain ...
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
About the Company : Supriya Lifescience Limited, established in 1987 and headquartered in Mumbai, is a globally recognized, technology-driven manufacturer of APIs, CDMO, and formulations. Its faciliti...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform delivering products and services across the full molecule lifecycle, from development to commercialization. With strong expe...
About the Company : Since 1962, MOEHS has produced high-quality Active Pharmaceutical Ingredients (APIs) for the global market. With decades of technical expertise, Moehs Group delivers pharmaceutical...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...

About the Company : Chr. Olesen Synthesis is a Danish manufacturer of APIs and advanced intermediates. Chr. Olesen Synthesis was established in 2012 after the Chr. Olesen Group acquisition of the mult...

About the Company : At Embio, technology is the foundation of our success, driving leadership in every product we manufacture. With 30+ years of expertise in bacterial, fungal, and Category 1 GMO biot...

About the Company : J&H CHEM is one of China's leading providers of integrated fine chemical services including offering, research and development, Custom manufacturing business, as well as other Valu...

About the Company : Viyash, true to its name, literally represents honesty and leadership in every sense. We are an integrated pharmaceutical company with a strong portfolio of niche formulations, ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 30MG
Approval Date : 2025-01-29
Application Number : 218987
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 40MG
Approval Date : 2025-01-29
Application Number : 218987
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2025-01-29
Application Number : 218987
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 60MG
Approval Date : 2025-01-29
Application Number : 218987
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 70MG
Approval Date : 2025-01-29
Application Number : 218987
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 10MG
Approval Date : 2024-12-16
Application Number : 219258
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 20MG
Approval Date : 2024-12-16
Application Number : 219258
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 30MG
Approval Date : 2024-12-16
Application Number : 219258
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 40MG
Approval Date : 2024-12-16
Application Number : 219258
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
Brand Name : LISDEXAMFETAMINE DIMESYLATE
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 50MG
Approval Date : 2024-12-16
Application Number : 219258
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory Info :
Registration Country : France
Brand Name : Lisdexamfetamine
Dosage Form : Oral-Dispersible Table...
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Packaging :
Regulatory Info :
Dosage : Oral-Dispersible Table...
Dosage Strength : 10MG
Brand Name : Lisdexamfetamine
Approval Date :
Application Number :
Registration Country : France
Regulatory Info :
Registration Country : France
Brand Name : Lisdexamfetamine
Dosage Form : Oral-Dispersible Table...
Dosage Strength : 70MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Packaging :
Regulatory Info :
Dosage : Oral-Dispersible Table...
Dosage Strength : 70MG
Brand Name : Lisdexamfetamine
Approval Date :
Application Number :
Registration Country : France
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 20MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 30MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 40MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 50MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 60MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 70MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 70MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Lisdexamfetamine Dimes...
Dosage Form : Immediate Release Chew...
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Immediate Release Chew...
Dosage Strength : 10MG
Brand Name : Lisdexamfetamine Dimes...
Approval Date :
Application Number :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Syrup
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : DMF, EXCiPAT, KOSHER, HALAL, W...
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : ProBlend (SMCC) is a co-processed excipient consists of microcrystalline cellulose & colloidal silicon dioxide, used as a diluent & binder in OSDs.
Pharmacopoeia Ref : USP-NF, DMF, EXCiPAT, KOSHER, ...
Technical Specs : NA
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Capsule
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Sallyso (Croscarmellose Sodium) is a cross-linked polymer of carboxymethylcellulose sodium, used as a superdisintegrant in tablets and capsules.
Pharmacopoeia Ref : USP-NF, BP, IP, EP, DMF, EXCiP...
Technical Specs : Sallyso 0.5 to 3.0%
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : Sucrex (Sucralose) is used as a sweetener and a taste masking agent in oral dosage forms such as tablets.
Pharmacopoeia Ref : USP-NF, BP, IP, EP, DMF, EXCiP...
Technical Specs : NA
Ingredient(s) : Sucralose
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Clinical Supply
Grade : Oral
Application : Empty Capsules
Excipient Details : ACGCAPS™ GC is specially designed for use in clinical trials and comes in the available sizes: AA, A & B.
Excipients Web Link
Dosage Form : Inhalation
Grade : Inhalation
Dosage Form : HardGel
Grade : Oral
Application : Empty Capsules
Excipient Details : ACGCAPS™ GL / HL is available in gelatin and cellulose (HPMC) material options and can be used for liquids, semi-liquids, hot-melts and combination fills.
Excipients Web Link
Dosage Form : HardGel
Grade : Oral
Application : Empty Capsules
Excipient Details : ACGCAPS™ GR can fulfill immediate release needs and is available in 15 sizes (from # 000 to # 5).
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Mannitol is used as a filler and binder in the manufacturing of oral solid dosage forms such as tablets.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Dosage Form : Granule / Pellet, Tablet
Grade : Oral
Category : Fillers, Diluents & Binders, Granulation, Solubilizers
Application : Fillers, Diluents & Binders, Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Dosage Form : Capsule, Granule / Pellet, Tablet, Injectable / Parenteral
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Thickeners and Stabilizers
Grade : Oral
Category : Co-Processed Excipients, Fillers, Diluents & Binders
Application : Co-Processed Excipients, Fillers, Diluents & Binders
Excipient Details : ProBlend (SMCC) is a co-processed excipient consists of microcrystalline cellulose & colloidal silicon dioxide, used as a diluent & binder in OSDs.
Pharmacopoeia Ref : USP-NF, DMF, EXCiPAT, KOSHER, ...
Technical Specs : NA
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Injectable / Parenteral, Tablet
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Application : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Excipient Details : D-Mannitol protects proteins from denaturation & degradation. It is used as a stabilizer in liquid products including biologic injectables & vaccines.
Pharmacopoeia Ref : USP, EP, BP, JP, ChP
Technical Specs : Low Endotoxin, Low Metals
Ingredient(s) : Mannitol
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Advantol® 300 is a DC pharmaceutical excipient used to create soft chew or fast melt oral dosage forms through co-processing technology.
Dosage Form : Capsule, Granule / Pellet, Tablet, Injectable / Parenteral
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Thickeners and Stabilizers
Application : Co-Processed Excipients, Fillers, Diluents & Binders
Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : DMF, EXCiPAT, KOSHER, HALAL, W...
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Dosage Form : Capsule, Granule / Pellet, Tablet, Injectable / Parenteral
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Thickeners and Stabilizers
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Advantol® 300 is a DC pharmaceutical excipient used to create soft chew or fast melt oral dosage forms through co-processing technology.
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Compressol® SM, co-processed polyol, is a DC excipient of mannitol & sorbitol with superior compactibility, low disintegration time & hygroscopicity.
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Disintegrants & Superdisintegrants
Brand Name : Mannogem Granular
Application : Chewable & Orodispersible Aids, Direct Compression, Disintegrants & Superdisintegrants
Excipient Details : Mannogem Granular has larger particles, offering a softer texture for chewable tablets and excellent flow, disintegration, and compression properties.
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Application : Direct Compression, Disintegrants & Superdisintegrants
Excipient Details : Mannogem 2080 exhibits excellent flow, disintegration and compression properties.
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Fillers, Diluents & Binders, Granulation
Excipient Details : AceCel is suitable for majority of the directly compressible actives, combines good flow and high compressibility.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Application : Direct Compression
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 440 g/l, Bulk density- 310 g/l; Particl...
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Disintegrants & Superdisintegrants, Granulation
Application : Empty Capsules
Excipient Details : ACGCAPS™ GL / HL is available in gelatin and cellulose (HPMC) material options and can be used for liquids, semi-liquids, hot-melts and combination fills.
Excipients Web Link
Application : Empty Capsules
Excipient Details : ACGCAPS™ GR can fulfill immediate release needs and is available in 15 sizes (from # 000 to # 5).
Application : Empty Capsules
Excipient Details : ACGCAPS™ GC is specially designed for use in clinical trials and comes in the available sizes: AA, A & B.
Excipients Web Link
Application : Empty Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : Size # 00el - 4
Ingredient(s) : Gelatin Excipient
https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
Global Sales Information
Shire Pharmaceutical Contracts Ltd
Dosage Form : Capsule, hard
Dosage Strength : 30 mg
Price Per Pack (Euro) : 100.749
Published in :
Country : Norway
RX/OTC/DISCN :

Shire Pharmaceutical Contracts Ltd
Dosage Form : Capsule, hard
Dosage Strength : 50 mg
Price Per Pack (Euro) : 116.70
Published in :
Country : Norway
RX/OTC/DISCN :

Shire Pharmaceutical Contracts Ltd
Dosage Form : Capsule, hard
Dosage Strength : 70 mg
Price Per Pack (Euro) : 132.52
Published in :
Country : Norway
RX/OTC/DISCN :

Dosage Form : Capsule, hard
Dosage Strength : 20 mg
Price Per Pack (Euro) : 94.281
Published in :
Country : Norway
RX/OTC/DISCN :

Dosage Form : Capsule, hard
Dosage Strength : 40 mg
Price Per Pack (Euro) : 107.052
Published in :
Country : Norway
RX/OTC/DISCN :

Dosage Form : Capsule, hard
Dosage Strength : 60 mg
Price Per Pack (Euro) : 123.00
Published in :
Country : Norway
RX/OTC/DISCN :

Dosage Form : CAPSULE;ORAL
Dosage Strength : 30MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE;ORAL
Dosage Strength : 70MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE;ORAL
Dosage Strength : 20MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 2,383
2018 Revenue in Millions : 0
Growth (%) : N/A

Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 2,559
2019 Revenue in Millions : 2,431
Growth (%) : 5

Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 2
2019 Revenue in Millions : 0
Growth (%) : New Launch in Japan

Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 2,652
2020 Revenue in Millions : 2,454
Growth (%) : 16

Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 5
2020 Revenue in Millions : 2
Growth (%) : 200

Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 3,220
2021 Revenue in Millions : 2,652
Growth (%) : 21

Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 10
2021 Revenue in Millions : 8
Growth (%) : 19

Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 2,978
2022 Revenue in Millions : 3,219
Growth (%) : 5

Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 2,713
2023 Revenue in Millions : 2,965
Growth (%) : -9

Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 2,014
2015 Revenue in Millions : 1,722
Growth (%) : 17

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
03 Dec 2025
Reply
15 Aug 2025
Reply
06 Aug 2025
Reply
03 May 2025
Reply
03 Apr 2025
Reply
12 Feb 2025
Reply
25 Jan 2025
Reply
06 Jan 2025
Reply
23 Oct 2024
Reply
03 Sep 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Reply
03 Sep 2024
Reply
26 Aug 2023
Reply
15 Feb 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
Patent Expiration Date : 2040-04-16
US Patent Number : 12433859
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 219847
Patent Use Code : U-842
Delist Requested :
Patent Use Description : INDICATED FOR THE TREA...
Patent Expiration Date : 2040-04-16

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 60 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 30 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 50 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 20 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 40 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 10mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 70 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 10 mg
Dosage Form : TABLET (CHEWABLE)
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 20 mg
Dosage Form : TABLET (CHEWABLE)
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23
Brand Name : VYVANSE
Patent Number : 2527646
Filing Date : 2004-06-01
Strength per Unit : 30 mg
Dosage Form : TABLET (CHEWABLE)
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2024-06-01
Date Granted : 2011-08-23

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
41
PharmaCompass offers a list of Lisdexamfetamine Dimesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lisdexamfetamine Dimesylate manufacturer or Lisdexamfetamine Dimesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lisdexamfetamine Dimesylate manufacturer or Lisdexamfetamine Dimesylate supplier.
PharmaCompass also assists you with knowing the Lisdexamfetamine Dimesylate API Price utilized in the formulation of products. Lisdexamfetamine Dimesylate API Price is not always fixed or binding as the Lisdexamfetamine Dimesylate Price is obtained through a variety of data sources. The Lisdexamfetamine Dimesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A elvanse manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of elvanse, including repackagers and relabelers. The FDA regulates elvanse manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. elvanse API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of elvanse manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A elvanse supplier is an individual or a company that provides elvanse active pharmaceutical ingredient (API) or elvanse finished formulations upon request. The elvanse suppliers may include elvanse API manufacturers, exporters, distributors and traders.
click here to find a list of elvanse suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A elvanse DMF (Drug Master File) is a document detailing the whole manufacturing process of elvanse active pharmaceutical ingredient (API) in detail. Different forms of elvanse DMFs exist exist since differing nations have different regulations, such as elvanse USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A elvanse DMF submitted to regulatory agencies in the US is known as a USDMF. elvanse USDMF includes data on elvanse's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The elvanse USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of elvanse suppliers with USDMF on PharmaCompass.
A elvanse written confirmation (elvanse WC) is an official document issued by a regulatory agency to a elvanse manufacturer, verifying that the manufacturing facility of a elvanse active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting elvanse APIs or elvanse finished pharmaceutical products to another nation, regulatory agencies frequently require a elvanse WC (written confirmation) as part of the regulatory process.
click here to find a list of elvanse suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing elvanse as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for elvanse API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture elvanse as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain elvanse and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a elvanse NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of elvanse suppliers with NDC on PharmaCompass.
elvanse Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of elvanse GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right elvanse GMP manufacturer or elvanse GMP API supplier for your needs.
A elvanse CoA (Certificate of Analysis) is a formal document that attests to elvanse's compliance with elvanse specifications and serves as a tool for batch-level quality control.
elvanse CoA mostly includes findings from lab analyses of a specific batch. For each elvanse CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
elvanse may be tested according to a variety of international standards, such as European Pharmacopoeia (elvanse EP), elvanse JP (Japanese Pharmacopeia) and the US Pharmacopoeia (elvanse USP).